Axsome files Form 144 to sell 49,670 shares
Axsome Therapeutics filed a Form 144 reporting an intended sale of 49,670 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Axsome Therapeutics filed a Form 144 reporting an intended sale of 49,670 shares of Common Stock. The shares were acquired on 03/15/2017 pursuant to stock options and the planned disposition is described as a cashless exercise / same-day sale. The filing lists 06/09/2026 as a related date.
Insights
Form 144 notice: an insider plans an exercise-and-sale of 49,670 shares acquired in 2017.
The filing shows 49,670 shares were acquired as compensation via stock options on 03/15/2017 and the proposed method is a cashless exercise / same-day sale. The Form 144 provides the regulatory notice required for sales by affiliates under Rule 144.
Timing and actual sale execution depend on broker/dealer processing and any Rule 144 volume or manner-of-sale limits; subsequent Form 4 or trade reports will show completion and proceeds.
Key Figures
Key Terms
cashless exercise financial
same-day sale financial
Form 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Axsome's Form 144 report about insider activity?
Will Axsome receive proceeds from this sale reported on Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.